On Thursday, Intra-Cellular Therapies received an upgrade to its Relative Strength (RS) Rating, from 71 to 86.
This proprietary rating identifies market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the trailing 52 weeks matches up against that of all other stocks.
Over 100 years of market history shows that the top-performing stocks typically have an 80 or better RS Rating in the early stages of their moves.
Risk Management In The Stock Market: How Much Money To Invest Now
While Intra-Cellular Therapies is not near an ideal buy point right now, see if it goes on to form and break out of a proper consolidation.
The company posted 0% EPS growth last quarter. Revenue increased 39%.
Intra-Cellular Therapies holds the No. 47 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Exelixis are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
